Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
However, all integrase inhibitors were associated with similar weight gain.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
A recent study sheds light on weight gain after switching to new form of tenofovir.
This may reflect loss of the weight-suppressing effect of the older version of the drug.
Aging with HIV won’t slow down Robert Gillum.
Some HIV meds are linked to weight gain, but we don’t yet know why.
The effect is greater for women, and it could have a detrimental effect on pregnancy outcomes at the population level.
People who switched from tenofovir disoproxil fumarate to tenofovir alafenamide gained weight regardless of other meds.
The global supply of tenofovir and six other important generic drugs must be ensured, warns a UNAIDS analysis.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
Tenofovir alafenamide is an updated version of tenofovir disoproxil fumarate that is tied to better bone and kidney health.
The observation that there have been Covid-19 infections in HIV+ persons on TDF/TAF argues against a complete protection from these agents.
Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.
Switching to new tenofovir tied to improved bone health in older people with HIV
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.